Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Promedior's new $21.5M series D helps advance fibrosis portfolio, including IPF and mylelofibrosis

This article was originally published in Scrip

Executive Summary

Promedior, a US company developing therapies for fibroproliferative diseases, has novel biologic candidates in some crowded investigational areas, but it believes its candidates offer a highly differentiated approach – and it hopes to have proof of concept data next year. The company has just gained a fresh $21.5 million injection of venture cash in a series D financing round, led by a new investor, Fibrotec Ventures LLC (which focuses on innovative fibrosis platforms).

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts